Key result
Standard-dose carvedilol plus amiodarone is linked to profound bradycardia, organ injury, and PEA arrest.
Why the study?
To emphasize the need for vigilance and cross-system medication reconciliation when failure to adjust pre- versus post-procedural doses of commonly prescribed medications leads to substantial morbidity.
Case Report (n=1)
Standard-dose carvedilol combined with amiodarone can cause severe synergistic AV-nodal blockade leading to life-threatening bradycardia, hypotension, and BRASH syndrome physiology.
Patients with cardiac and metabolic comorbidities often undergo procedural intervention as well as pharmacological management. Medication adjustment is made in anticipation of and/or as a response to procedures. We present a case where failure to track and verify pre- versus post-procedural doses of a commonly prescribed medication led to substantial morbidity. This report emphasizes the need for vigilance even when using medications generally considered safe and for enhanced information sharing across different electronic medical record systems. A 61-year-old Hispanic man with hypertension, type 2 diabetes mellitus, and recent direct current cardioversion (DCCV) for new-onset atrial fibrillation was readmitted to the hospital for dyspnea. He had been recently discharged from the hospital for atrial fibrillation after being cardioverted to normal sinus rhythm. He was maintained, however, on carvedilol 25 mg twice daily—the same dose prescribed to him prior to DCCV—resulting in bradycardia, relative hypotension, acute kidney and liver injury. A few months later, at an elective admission at another hospital, he underwent ablation for refractory atrial fibrillation and was inappropriately restarted on the previous carvedilol dose; subsequently he had bradycardia and two Pulseless electrical activity (PEA) arrests. This case highlights that intolerance to Atrioventricular (AV)-nodal blockade and Bradycardia, Renal failure, AV nodal blockade, Shock, and Hyperkalemia (BRASH) physiology can occur at standard dosing, particularly with drug interactions and hemodynamic vulnerability. It underscores the importance of rigorous medication reconciliation, anticipatory de-escalation of rate-controlling agents after rhythm-control procedures, and improved cross-system access to prior adverse drug events. In the long term, individualized precision medicine may reduce adverse reactions to widely used medications at commonly prescribed doses.
No takes yet. Share an insight, caveat, or question.
Kaminski et al. (2026) conducted a case report in Atrial fibrillation (n=1). Carvedilol in combination with amiodarone was evaluated on Adverse events (bradycardia, hypotension, acute kidney and liver injury, PEA cardiac arrest). Standard-dose carvedilol combined with amiodarone resulted in profound bradycardia, relative hypotension, acute kidney and liver injury, and ultimately pulseless electrical activity cardiac arrests.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: